ID   HOUA-I
AC   CVCL_3867
SY   HOUA-1; HOUAI; HOUA
DR   CLO; CLO_0050886
DR   BioSample; SAMN03472265
DR   cancercelllines; CVCL_3867
DR   Cosmic; 713498
DR   Cosmic; 1241348
DR   Cosmic; 1622897
DR   DepMap; ACH-002027
DR   IARC_TP53; 2378
DR   RCB; RCB0659
DR   Wikidata; Q54890187
RX   CelloPub=CLPUB00051;
RX   PubMed=2429643;
RX   PubMed=2448191;
RX   PubMed=8105795;
RX   PubMed=9436037;
RX   PubMed=10457904;
RX   PubMed=15901131;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~50 hours (CelloPub=CLPUB00051); 56 hours (PubMed=10457904).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=8105795).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=8105795).
CC   Misspelling: HOOUA; Cosmic=1241348.
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
ST   Source(s): DepMap; RCB
ST   Amelogenin: X
ST   CSF1PO: 13,14,15 (DepMap)
ST   CSF1PO: 14,15 (RCB)
ST   D13S317: 13,14,15
ST   D16S539: 9,13,14 (RCB)
ST   D16S539: 9,13,14,15 (DepMap)
ST   D18S51: 17,18,19,23,24,25
ST   D21S11: 31,32
ST   D3S1358: 16,17
ST   D5S818: 12,13,14,15 (DepMap)
ST   D5S818: 12,14,15 (RCB)
ST   D7S820: 10,11,12
ST   D8S1179: 12,13,15
ST   FGA: 17,21
ST   Penta D: 11
ST   Penta E: 13,15,16
ST   TH01: 6,9
ST   TPOX: 8,9
ST   vWA: 18,19,20
DI   NCIt; C7558; Endometrial carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A778 ! HOUA-II
SX   Female
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   CelloPub=CLPUB00051;
RA   Ishikawa I., Soma M., Ono I., Nakaguchi T., Ishawata C., Nozawa S.,
RA   Ishikawa H.;
RT   "Biological characteristics of adenocarcinoma cell line (HOUA-I) and
RT   B-lymphoblastoid cell line (HOUA-II) established from the same tissue
RT   of endometrial adenocarcinoma.";
RL   Jikeikai Med. J. 36:303-315(1989).
//
RX   PubMed=2429643; DOI=10.1111/j.1447-0756.1986.tb00192.x;
RA   Ishiwata I., Ishiwata C., Nozawa S., Ishikawa H.;
RT   "CA125 production by gynecologic tumors in vitro and its modulation
RT   induced by dibutyl cyclic adenosine monophosphate.";
RL   Asia Oceania J. Obstet. Gynaecol. 12:285-290(1986).
//
RX   PubMed=2448191; DOI=10.1016/0090-8258(88)90151-5;
RA   Ishiwata I., Ishiwata C., Soma M., Ono I., Nakaguchi T., Ishikawa H.;
RT   "Tumor angiogenic activity of gynecologic tumor cell lines on the
RT   chorioallantoic membrane.";
RL   Gynecol. Oncol. 29:87-93(1988).
//
RX   PubMed=8105795; DOI=10.1002/mc.2940080303;
RA   Enomoto T., Fujita M., Inoue M., Nakazawa-Miyamoto A., Tanizawa O.,
RA   Nomura T.;
RT   "Alterations of the Rb gene and its association with Ki-ras activation
RT   and p53 inactivation in endometrial adenocarcinoma.";
RL   Mol. Carcinog. 8:132-137(1993).
//
RX   PubMed=9436037;
RA   Soma M., Ishiwata I., Ishiwata C., Nakaguchi T., Ono I., Kiguchi K.,
RA   Hashimoto H., Tachibana T., Ishikawa H., Nozawa S.;
RT   "Tissue reconstruction of gynecologic tumor cells in the rotation
RT   culture system.";
RL   Hum. Cell 10:175-181(1997).
//
RX   PubMed=10457904;
RA   Ishiwata I., Sudo T., Kiguchi K., Ishikawa H.;
RT   "Tumor angiogenesis factors produced by cancer cells.";
RL   Hum. Cell 12:37-46(1999).
//
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.;
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).
//